Abstract: p53 is a transcription factor central to cellular DNA metabolism that controls the cellular responses to DNA damage. p53 activity, finely regulated, integrates the information from several pathways to preserve the cell's genetic information. Great attention has been given to the structural determination of p53 domains and its cancerous mutants because 50% of cancer cases present mutations in p53 that hinders its activity resulting in uncontrolled cell reproduction. We enumerate the multiple studies carried to elucidate the structure of p53 domains and we highlight their main findings. The ultimate goal of the reviewed structural efforts is to understand p53 function at atomic level with the aim to overcome cancer by reversing p53 mutant activity to its normal function.
INTRODUCTION
The protein p53 has a central role in how the cell responds to stress signals by regulating genes that induce DNA repair, cell arrest and cell death. When p53 is active, it prevents cell reproduction in conditions that might otherwise result in passing damaged DNA to newly divided cells [1] . To understand the structural bases of p53 function and regulation is key to understand cancerous processes because mutations in p53 are ubiquitous in many cases of human cancer [2] . For example, in ovary, esophagus, colorectum, head and neck and pancreas cancer cases around 50% of the cells present a mutation in p53 [3] . In other common human cancers, like lung, skin, bladder, stomach, brain and liver, more than 30% of the cells carry a mutant in a p53 allele [3] .
Human p53 is a polypeptide of 393 amino acids that is organized in five domains ( Fig. 1) : the N-terminal amino acid sequence forms the transactivation domain that induces transcriptional activation of genes regulated by p53; the proline-rich domain that promotes p53 interaction with other proteins; the DNA-binding domain that recognizes the consensus sequences of promoters activated by p53; the tetramerization domain; and the regulatory domain in the Cterminus that can be chemically modified or labeled with ubiquitin molecules to target p53 for degradation by the proteosome. There is also a bipartite nuclear localization sequence (NLS), in between the DNA-binding domain and the tetramerization domain with KR amino acids in positions 305 and 306 and KKK in positions 319 to 321, that promotes p53 transport to the nucleus. It has been impossible until now to determine the three dimensional structure of the full length structure of p53 due to the presence of large intrinsically unfolded regions, particularly in the N-and Ctermini [4] . All the successful efforts towards determining the atomic three dimensional structure of p53 have focused on individual domains. The first structures to be solved were the DNA binding domain in complex with DNA [5] and the tetramerization domain [6] [7] [8] [9] . Shortly after, a complex with a *Address correspondence to this author at the Department of Chemistry and Biochemistry, University of California San Diego, 9500 Gilman Dr. MC 0378, La Jolla, CA; E-mail: viadiu@ucsd.edu portion of the transactivation domain was solved [10] and recently fragments of the regulatory domain also in complex with other proteins were determined [11] [12] [13] . In the following sections, we review the known atomic structures of p53 domains determined by X-ray crystallography and nuclear magnetic resonance, besides new structural information on full length p53 obtained by electron microscopy single particle reconstruction.
TRANSACTIVATION AND PROLINE-RICH DOMAINS
The N-terminus of p53 lacks a stable tertiary structure and has only a weak tendency in solution to form some secondary structure [14] . Based on its amino acid sequence, the N-terminus of p53 has been divided into two domains: the first segment of 64 amino acids, with a high content of aspartic and glutamic acid residues, forms the transactivation domain and the sequence between residues 65 and 92 forms the proline-rich domain (Fig. 1) . According to the target genes that are activated, the N-terminus has been divided in a transcriptional activation domain 1 (AD1: residues 1-42) and a transcriptional activation domain 2 that also comprises the proline-rich domain (AD2: residues 43-92). Both functional domains can interact with the transcriptional machinery of the cell to promote transcription of p53 regulated genes. AD1 triggers the transcription of cell arrest genes, while AD2 promotes the activation of apoptotic genes [15] .
The known structures of p53 transactivation domains have only been solved in complex with their binding proteins ( Table 1) , when the p53 fragments acquire a helical conformation (Fig. 2) . The transactivation domain 1 of p53 is able to interact with numerous proteins, some regulatory, like MDM2, and others involved directly in transcription, as TBP, TAFII31, TAFII70 and p300/CBP [16] . In the other hand, the transactivation domain 2 of p53 also interacts with transcriptional proteins and the proline rich region can bind proteins with SH3 domains [16] . The atomic structure of transactivation domain 1 of p53 (residues 17-27), normally unstructured, acquires a helical conformation when is bound to the N-terminal domain of MDM2 [10] (Fig. 2a) . While an intrinsically unfolded segment of transactivation domain 2 of p53 (residues 33-56) in complex with replication protein A (RPA) forms a long kinked alpha helix upon complex formation ( Fig. 2b) [17] .
DNA-BINDING DOMAIN
More than 80% of mutations present in human tumors are found in the central region of p53 (residues 93-292) that specifically recognizes DNA [3] . The DNA-binding domain structure has been solved in the presence and absence of DNA ( Table 2 ). The first structural study on p53 determined the crystal structure of its DNA-binding domain as a monomer bound to a 10 base pair DNA motif [5] . The structure is formed by an immunoglobulin-like anti-parallel -sandwich with a loop-sheet-helix motif and two large loops. DNA is recognized by the loops and the loop-sheethelix motif and most of the mutations found in tumors are localized in these regions. Based on the observed structure, cancer hot spot mutants were classified in two groups: whether they affect residues directly in contact with DNA (R248 or R273) or they distort the overall protein fold (R175, G245, R249 and R282) [5] . In the absence of DNA, the p53 -sandwich fold remains unchanged with respect to the structure in complex with DNA (Fig. 3a) , but one of the DNA recognition loops adopts a different conformation that rearranges upon DNA binding to recognize the bases [18] . p53 binds specifically as a tetramer to two 10 base pair DNA sequences with a consensus sequence of RRRCW WGYYY (where R=A or G, W=A or T and Y=C or T) and a spacing of 0 to 13 base pairs in between each decameric recognition sequence [19] . Recently, the determination of four structures of the DNA binding domain bound to four different DNA half-sites showed that tetrameric p53 binds to DNA as a dimer of dimers with stabilizing protein-protein interactions between the monomers and small rearrangements in the DNA-protein interface to accommodate the different DNA sequences (Fig. 3b) [20] .
An important structural effort to understand the effect of common oncogenic mutants has also been started ( Table 2 ) [21] [22] [23] . It has demonstrated that, besides mutations that directly affect DNA contacts, other oncogenic mutations create an unstable p53 protein by forming cavities in its structure, distort their DNA binding surface or alter the protein-protein interactions that promote tetramer formation. The ultimate vital goal of the characterization of p53 mutants Fig. (3) Structures of the p53 DNA Binding Domain. a) Mouse p53 (residues 99-284) (PDB ID 1HU8) [18] . b) Human p53 tetramer (residues 94-293) bound to two DNA half-sites (PDB ID 2AC0) [20] . is the molecular understanding of its inactivation to potentially rescue its activity with drugs [2] .
TETRAMERIZATION DOMAIN
The structure of the tetramerization domain of p53 comprises residues 324 to 361 (Fig. 1) and it has been solved by X-ray crystallography and NMR ( Table 3) . It is formed, similarly to the tetrameric DNA binding domain, by a dimer of dimers. It starts with a strand and after a turn continues with an helix (Fig. 4) . The orientation between the two dimers in the crystal structure is 80 degrees [9] , while in the NMR structures the angle between the dimers is somewhat lower [8, 24] . The structure of several mutants that disrupt tetramer formation, but are stable as dimers have also been solved by NMR [25, 26] . The observation that p53 forms a tetramer has important functional consequences. Inactive p53 monomers with mutations in other domains behave as dominant-negative phenotypes causing cancer in a heterozygous phenotype when the intact tetramerization domain is able to sequester functional monomers resulting in an inactive heterotetramer.
REGULATORY DOMAIN
The p53 regulatory domain consists of the last 30 amino acids in the protein C-terminal comprising residues 362 to 393. This domain has a basic character because its large number of lysines and arginines (Fig. 1) . It can suffer many modifications including acetylation, methylation, phosphorylation and ubiquitination for its further degradation by the proteosome. Analogous to the N-terminus, the C-terminus of p53 is an intrinsically unfolded protein that acquires some stable secondary structure when is bound to other proteins [4] .
For some complexes of p53 regulatory domain with their binding proteins the atomic structure has been solved ( Table  4) . p53 regulatory domain can adopt different conformations depending on the binding partner. For example, in complex with S100B [11] or in complex with phospho-CDK2-cyclin A [13] , p53 regulatory domain presents a helical structure (Figs. 5a and 5c) . Instead, when the regulatory domain is bound to the deacetylase Sir2 [27] or to the bromodomain of CBP [28] , it has an extended conformation (Figs. 5b and  5d) .
STRUCTURE OF FULL-LENGTH P53
In the past few years, the three dimensional reconstruction of protein structures using electron micrographs have emerged as an ideal technique to study large protein complexes that show conformational heterogeneity and are difficult to crystallize or study by NMR. The size of the p53 tetramer, about 43kDa for the monomer and less than 200kDa for the tetramer, makes it one of the smallest proteins ever studied by electron microscopy single particle reconstruction [29, 30] . Two innovative EM studies obtained different results, probably, due to inherent sample heterogeneity, the method used to prepare the microscopy sample and the chosen symmetry constraints for the 3D reconstruction. Using cryo-electron microscopy and D2 symmetry with a murine p53 sample, a ~14Å resolution reconstruction resembling a hollow skewed cube was calculated and interpreted as the monomers in the p53 tetramer having an upside-down arrangement where the N-terminus and Cterminus of adjacent monomers interact [29] ; this interpretation differs with ensuing crystallographic data [20] . When negative-stained particles and a C2 symmetry was used to analyze a human p53 sample in the presence and absence of DNA, a compacted ~25Å resolution reconstruction resulted that showed no difference between the protein alone or in complex with DNA and hinted to the N- [11] . b) Human acetylated p53 (residues 381-387) in complex with Sir2 (PDB ID 1MA3) [12] . c) Human p53 (residues 378-386) in complex with phospho-CDK2-cyclin A [13] . d) Human acetylated p53 (residues 366-385) in complex with CBP bromodomain [28] . and C-termini being exposed to the solvent where they could interact with other proteins. Cryo-electron microscopy studies at higher resolution are needed to allow an unambiguous fitting of the known crystal structures to the electron microscopy maps.
FUTURE PERSPECTIVES
A detailed understanding of p53 function is vital for the ultimate cure of cancer. p53 has a central role in the cellular response to DNA damage and its genetic integrity. When modified by the addition of a phosphate group, p53 is able to accumulate in the cell nucleus activating the cell arrest or apoptotic pathways that protect the cell from reproducing when DNA damage has occurred. In contrast, when p53 is in a dephosphorylated state, it is degraded and their transcriptional activity stops. A cancerous process emerges when a mutation disrupts p53 from triggering transcription when DNA is damaged.
We have mentioned the multiple pioneer studies on p53 that have provided us with a clear understanding of the structure of p53 individual domains and their overall role in the function of the protein. Nonetheless, many questions remain yet to be answered regarding the interactions of p53 domains with each other and the functional role of such interactions in the regulation of p53 activity. With the knowledge of the atomic structure of the domains that have a well-defined structure, future work will focus on elucidating the interaction among the different domains of p53 to 
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Human 367-388 p53 peptide becomes helical in complex with S100B. NMR 2000 [11] understand how protein modifications and conformational changes in p53 regulate its transcriptional activity.
The structures of the DNA-binding and tetramerization domains of p53 are well studied and understood (Tables 2  and 3) . Nonetheless, the majority of posttranslational modifications that regulate p53 (phosphorylation, methylation, acetylation, ubiquitylation, neddylation and sumoylation) occur in the activation and regulatory domains [1] , but, due to their intrinsically disordered character they have been harder to define structurally and only the structure of some fragments are known (Tables 1 and 4) . Such intrinsic disorder is likely to confer these regions a greater flexibility to bind multiple proteins allowing them to integrate information from various pathways to regulate the gene expression of different pathways. Future structural progress on p53 should focus in understanding how p53 complex activity results from the interplay between its different domains and how posttranslational modifications of p53 regulate its activity.
